Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,771 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral Medication Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

AV650 Drug-Drug Interaction Study

NCT00456560
View directory record Official record
Conditions
Healthy
Interventions
AV650, Fluvoxamine, Paroxetine
Drug
Lead sponsor
Avigen
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2007 · Synced Sep 2, 2026, 5:23 AM EDT
Recruiting Phase 4 Interventional

Secondhand Tobacco Smoke and Cardiovascular Disease

NCT04715568
View directory record Official record
Conditions
Cardiovascular Diseases, Hypertension
Interventions
Losartan, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis

NCT02342691
View directory record Official record
Conditions
Gingival Inflammation
Interventions
BLXA4, Placebo oral rinse
Drug
Lead sponsor
The Forsyth Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated Phase 1 Interventional

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

NCT05631574
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC, PDAC, CRC, Relapsed Cancer, Refractory Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage III NSCLC, Stage IV NSCLC, KRAS Mutation-Related Tumors
Interventions
BMF-219
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Goodyear, Arizona • Encinitas, California • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults

NCT04147715
View directory record Official record
Conditions
Healthy Volunteer
Interventions
S-648414, Placebo, Midazolam, Dolutegravir
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection

NCT02378935
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
VOX, SOF/VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
31
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 2 Interventional

Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

NCT01455090
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
BMS-650032, BMS-790052, BMS-791325, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
26
States / cities
Birmingham, Alabama • Coronado, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Sep 2, 2026, 5:23 AM EDT
Recruiting Phase 1 Interventional

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

NCT06639724
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)
Combination Product
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)

NCT01253408
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated Phase 2 Interventional Results available

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

NCT00365274
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma
Interventions
Cyclophosphamide, Doxorubicin hydrochloride, vincristine sulfate, prednisone, SGN-30
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Buprenorphine Naltrexone-P1 A-Cocaine

NCT00733720
View directory record Official record
Conditions
Cocaine-related Disorders
Interventions
Suboxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 2, 2026, 5:23 AM EDT
Withdrawn Phase 4 Interventional

Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)

NCT01299220
View directory record Official record
Conditions
Skin Rash
Interventions
Acitretin
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 2, 2026, 5:23 AM EDT
Withdrawn Phase 4 Interventional

Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis

NCT03626376
View directory record Official record
Conditions
Herpes Simplex Virus Keratitis
Interventions
oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily, oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Sep 2, 2026, 5:23 AM EDT
Withdrawn Phase 4 Interventional

Buprenorphine/Naloxone Micro-Dosing for Postoperative Pain Management in Opioid-Tolerant Patients

NCT04771689
View directory record Official record
Conditions
Post-operative Pain
Interventions
Buprenorphine/Naloxone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated Phase 1 Interventional

Study of GS-1219 in Participants With HIV-1

NCT07115368
View directory record Official record
Conditions
HIV-1-infection
Interventions
GS-1219, BVY, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy Adults

NCT05807490
View directory record Official record
Conditions
Healthy
Interventions
PF-07328948, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Sep 2, 2026, 5:23 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting

NCT07210125
View directory record Official record
Conditions
HIV
Interventions
Lenacapavir long-acting, Standard of Care (SOC)
Drug · Other
Lead sponsor
Kelley-Ross & Associates, Inc.
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 1 Interventional

Study of GemOx and Vandetanib in Advanced Solid Malignancy

NCT00660725
View directory record Official record
Conditions
Advanced Incurable Solid Malignancy
Interventions
Vandetanib, Gemcitabine, Oxaliplatin
Drug
Lead sponsor
Leonard Appleman
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures

NCT01721317
View directory record Official record
Conditions
Seizures
Interventions
Ezogabine/Retigabine IR, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
9
States / cities
Fresno, California • Santa Monica, California • Colorado Springs, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Sep 2, 2026, 5:23 AM EDT
Enrolling by invitation Phase 2 Interventional

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

NCT05669989
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone, Lenalidomide, Pomalidomide, Isatuximab subcutaneous (SC), Carfilzomib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120

NCT02489513
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-AG-120
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)

NCT02535715
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ORMD-0801 capsules- 2x8mg, ORMD-0801 capsules- 3x8mg, ORMD-0801 capsules- 1x16mg
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Sep 2, 2026, 5:23 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia

NCT03781115
View directory record Official record
Conditions
Schizophrenia
Interventions
Ziprasidone, Olanzapine, Placebo Comparator
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia

NCT04467840
View directory record Official record
Conditions
COVID-19, Lung Infection
Interventions
Opaganib, Placebo
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 2, 2026, 5:23 AM EDT